Table 1.
Baseline patient characteristics.
| Characteristic | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| PVP group (n = 109) | PKRP group (n = 106) | P Value | PVP group (n = 60) | PKRP group (n = 60) | P Value | |
| Age (year) | 72.68 ± 6.95 | 67.47 ± 7.39 | < 0.001 | 70.37 ± 6.09 | 71.12 ± 6.07 | 0.500 |
| BMI (kg/m2) | 21.93 ± 3.23 | 21.30 ± 3.16 | 0.146 | 21.68 ± 3.25 | 21.13 ± 3.12 | 0.341 |
| PV (g) | 63.19 ± 19.94 | 54.60 ± 21.00 | 0.002 | 59.40 ± 21.38 | 60.02 ± 20.33 | 0.872 |
| tPSA (ng/ml) | 5.18 ± 3.15 | 3.43 ± 2.48 | < 0.001 | 4.07 ± 2.56 | 4.15 ± 2.64 | 0.856 |
| IPSS | 23.13 ± 3.80 | 21.74 ± 3.69 | 0.007 | 21.98 ± 4.30 | 22.92 ± 2.98 | 0.169 |
| QoL | 4.93 ± 0.65 | 4.79 ± 0.67 | 0.138 | 4.77 ± 0.70 | 4.97 ± 0.52 | 0.078 |
| Qmax (ml/s) | 6.63 ± 2.27 | 7.31 ± 2.40 | 0.034 | 7.24 ± 2.43 | 6.70 ± 1.84 | 0.176 |
| PVR (ml) | 84.06 ± 60.80 | 72.18 ± 59.87 | 0.150 | 72.32 ± 62.27 | 80.40 ± 55.78 | 0.455 |
| IIEF-5 | 8.04 ± 1.67 | 8.96 ± 2.11 | < 0.001 | 8.37 ± 1.79 | 8.27 ± 2.11 | 0.780 |
| MSHQ | 41.61 ± 18.98 | 48.38 ± 15.91 | 0.005 | 46.07 ± 17.59 | 43.10 ± 16.90 | 0.348 |
| MSHQ-EjD | 12.08 ± 5.02 | 14.16 ± 5.48 | 0.004 | 12.87 ± 5.21 | 12.00 ± 5.18 | 0.362 |
| Charlson CI | 0.035 | 0.678 | ||||
| 0 | 42 | 49 | 27 | 22 | ||
| 1 | 37 | 42 | 18 | 26 | ||
| 2 | 21 | 14 | 9 | 12 | ||
| 3 | 9 | 1 | 6 | 0 | ||
BMI body mass index, PV prostate volume, tPSA total prostate-specific antigen, IPSS international prostate symptom score, QoL quality of life score, Qmax maximal urinary flow rate, PVR postvoid residual, IIEF-5 international index of erectile function-five term score, MSHQ male sexual health questionnaire score, MSHQ-EjD male sexual health questionnaire on ejaculatory dysfunction score, Charlson CI charlson comorbidity index.